Mathematical model for chemotherapeutic drug efficacy in arresting tumour growth based on the cancer stem cell hypothesis

Cell Proliferation

Volumn 40, Issue 3, 2007, Pages 338-354

  Ganguly, R ^a,b   Puri, I K ^a  

^a State University   (United States)

^b JADAVPUR UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; IMATINIB;

ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER RECURRENCE; CANCER STEM CELL; CELL KILLING; CELL POPULATION; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTINUOUS INFUSION; DANDELION; DRUG EFFICACY; DRUG INFUSION; DRUG INTERMITTENT THERAPY; DRUG RESPONSE; HYPOTHESIS; KINETICS; MATHEMATICAL MODEL; PROGNOSIS;

ANTINEOPLASTIC AGENTS; CELL COMPARTMENTATION; CELL DIVISION; CELL SURVIVAL; HUMANS; MODELS, BIOLOGICAL; PREDICTIVE VALUE OF TESTS; SIGNAL TRANSDUCTION; TUMOR STEM CELLS;

TARAXACUM OFFICINALE;

EID: 34249101545     PISSN: 09607722     EISSN: 13652184     Source Type: Journal    
DOI: 10.1111/j.1365-2184.2007.00434.x     Document Type: Article

References (35)

1. Al-Hajj M, Becker MW, Wicha M, Weismann I, Clark MF (2004) Therapeutic implications of cancer stem cells. Curr. Opin. Genet. Dev. 14, 43 47.
2. Al-Hajj M, Clarke MF (2004) Self-renewal and solid tumor cells. Oncogene 23, 7274 7282.
3. Bonifazi F, de Vivo A, Rosti G, Guilhot J, Trabacchi E, Hehlmann R, Hochhaus A, Shepherd PC, Steegmann JL, Kluin-Nelemans HC, Thaler J, Simonsson B, Louwagie A, Reiffers J, Mahon FX, Montefuso E, Alimena G, Hasford J, Richards S, Saglio G, Testoni N, Martinelli G, Tura S, Baccarani M (2001) Chronic myeloid leukaemia and interferon-alpha: a study of complete cytogenic responders. Blood 98, 3074 3081.
4. Brenton JD, Carey LA, Ahmed AA, Caldas C (2005) Molecular classification and molecular forecasting of breast cancer: ready for clinical application. J. Clin. Oncol. 23, 7350 7360.
5. Byrne HM (2003) Modeling avascular tumour growth. In : Preziosi L, ed. Cancer Modeling and Simulation, p. 75. London : Chapman & Hall / CRC.
6. Clarke MF (2004) At the root of brain cancer. Nature 432, 281 282.
7. Cortes J, O'Brien S, Kantarjian H (2004) Discontinuation of imanitib therapy after achieving a molecular response. Blood 104, 2204 2205.
8. Ganguly R, Puri IK (2006) Mathematical model for the cancer stem cell hypothesis. Cell Prolif. 39, 3 14.
9. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100, 57 70.
10. Huff CA, Matsui WH, Smith BD, Jones RJ (2006) Strategies to eliminate cancer stem cells: clinical applications. Eur. J. Cancer 42, 1293 1297.
11. Huntly BJ, Gilliland DG (2005) Summing up cancer stem cells. Nature 435, 1169 1170.
12. Jessell TM, Lumsden A (1997) Inductive signals and the assignment of cell fate in the spinal cord and hindbrain. In : Cowan WM, Jessell TM, Zipursky SL, eds. Molecular and Cellular Approaches to Neural Development, p. 290. Oxford : Oxford University Press.
13. Jones RJ, Matsui WH, Smith BD (2004) Cancer stem cells: are we missing the target. J. Natl. Cancer Inst. 96, 583 585.
14. Komarova NL, Wadarz. D (2005) Drug resistance in cancer: principles of emergence and prevention. PNAS 102, 9714 9717.
15. Lessard J, Sauvageau G (2003) Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature 15, 255 260.
16. Mackenzie IC (2005) Retention of stem cell patterns in malignant cell lines. Cell Prolif. 38, 347 355.
17. Maddrey AM, Bergeron JA, Lombardo ER, McDonald NK, Mulne AF, Barenberg PD, Bowers DC (2005) Neuropsychological performance and quality of life of 10 year survivors of childhood medulloblastoma. J. Neurooncol. 72, 245 253.
18. Mauro MJ, Druker BJ, Kuyl J, Kurilik G, Maziarz. RT (2003) Increasing levels of detectable leukaemia in imanitib treated CML patients with previously undetectable or very low levels of BCR-ABL. Proc. ASCO 22, 569.
19. Mayer LD, Harasym TO, Tardi PG, Harasym NL, Shew CR, Johnstone SA, Ramsay EC, Bally MB, Janoff AS (2006) Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumour-bearing mice. Mol. Cancer Ther. 5, 1854 1863.
20. Michor F, Hughes TP, Iwasa Y, Branford S, Shah N, Sawyers CL, Nowak MA (2005) Dynamics of chronic myeloid leukaemia. Nature 435, 1267 1270.
21. Molofsky A, Pardal R, Iwashita T, Park I-K, Clarke MF, Morrison SJ (2003) Bmi-1 dependence distinguishes neural stem cell self-renewal from progenitor proliferation. Nature 425, 962 967.
22. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman JM, Kantarjian H, Taylor K, Verhoef G, Bolton AE, Capdeville R, Druker BJ IRIS Investigators (2003) Imanitib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukaemia. N. Engl. J. Med. 348, 994 1004.
23. O'Neill A, Schaffer DV (2004) The biology and engineering of stem cell control. Biotechnol. Appl. Biochem. 40, 5 16.
24. Oliver TG, Wechsler-Reya RJ (2004) Getting at the root and stem of brain tumour. Neuron 42, 885 888.
25. Pardal R, Clarke MF, Morrison SJ (2003) Applying the principle of stem cell biology to cancer. Nat. Rev. Cancer 3, 895 902.
26. Pierce A, Smith DL, Jakobsen LV, Whetton AD, Spooncer E (2001) The specific enhancement of interferon alpha induced growth inhibition by BCR/ABL only occurs in multipotent cells. Hematol. J. 2, 257 064.
27. Polakis P (2000) Wnt Signaling and cancer. Genes Dev. 14, 1837 1851.
28. Polyak K, Hahn WC (2006) Roots and stems: stem cells in cancer. Nat. Med. 12, 296 300.
29. Reya T, Morrison SJ, Clarke MF, Weissman IL (2001) Stem cells, cancer, and cancer stem cells. Nature 414, 105 111.
30. Roeder I, Horn M, Glauche I, Hochhaus A, Mueller MC, Loeffler M (2006) Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications. Nat. Med. 12, 1181 1184.
31. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB (2004) Identification of human brain tumor initiating cells. Nature 432, 396 401.
32. Stordal BK, Davey MW, Davey RA (2006) Oxaliplatin induces drug resistance more rapidly than cisplatin in H69 small cell lung cancer cells. Cancer Chemother. Pharmacol. 58, 256 265.
33. Taipale J, Beachy PA (2001) The Hedgehog and Wnt signaling pathways in cancer. Nature 411, 349 254.
34. Viswanathan S, Zandstra P (2003) Towards predictive models of stem cell fate. Cytotechnol. 41, 75 92.
35. Wichmann HE, Loeffler M (1984) Mathematical Modeling of Cell Proliferation: Stem Cell Regulation in Hemopoiesis, Vol. I. Boca Raton, FL : CRC Press.